Search

Your search keyword '"G Lucisano"' showing total 9 results
Start Over Author "G Lucisano" Topic medicine.medical_specialty
9 results on '"G Lucisano"'

1. Arsenic metabolism and urothelial cancer risk: a systematic review and meta-analysis

Author

P Scampoli, Tommaso Staniscia, F Cedrone, F Meo, P Di Giovanni, G Lucisano, and G Di Martino

Subjects
Oncology, medicine.medical_specialty, chemistry, business.industry, Meta-analysis, Internal medicine, Public Health, Environmental and Occupational Health, medicine, Urothelial cancer, chemistry.chemical_element, business, Arsenic
Abstract

Background Arsenic is a toxic metalloid element frequently found in the environment. Chronic arsenic exposure is a critical public health issue in many countries since the identification of arsenic and its compounds as human carcinogens by the World Health Organization. After absorption, inorganic arsenic (iAs) is mainly methylated into monomethylated and dimethylated compounds (MMA, DMA), which are then excreted through the kidney together with unmethylated iAs. Whether the methylation process is to detoxify or potentiate arsenic toxicity, however, remains an ongoing debate. The purpose of this systematic review was to conduct a comprehensive meta-analysis to estimate the association between arsenic exposure and urothelial cancer. Methods 10 observational studies met the inclusion criteria and were included in the systematic review. IAs%, MMA% and DMA% were extracted from each paper. Weighted Mean Differences with 95% confidence intervals were defined according to Cases minus Controls. Pooled risk estimates from individual studies were assessed using random effects models. Meta-regression analysis was performed to estimate the extent of urothelial cancer risk as a function of iAs%, MMA% and DMA%. Results Results showed as patients with urothelial cancer presented higher level of urinary iAs% (WMD 2.70, 95%CI 0.64-4.76), MMA% (WMD 2.81, 95%CI 1.43-4.20) and DMA% (WMD-3.44, 95%CI-6.57–0.30). Conclusions These findings suggest that higher level of iAs% and MMA% and lower level of DMA% were associated with an increased risk of urothelial cancer. Additional population based studies are needed to understand the role of arsenic in cancer development. Understanding the meaning of arsenic metabolism could improve the risk assessment of arsenic toxicity and provide a potential tool for disease prediction and prevention. Key messages Higher level of iAs%, MMA% and DMA% were associated with an increased risk of urothelial cancer. Understanding the meaning of arsenic metabolism could improve the risk assessment of arsenic toxicity.

Published
2019

2. Healthcare resource use, direct and indirect costs of hypoglycemia in type 1 and type 2 diabetes, and nationwide projections. Results of the HYPOS-1 study

Author

C.B. Giorda, M.C. Rossi, O. Ozzello, S. Gentile, A. Aglialoro, A. Chiambretti, F. Baccetti, F.M. Gentile, F. Romeo, G. Lucisano, A. Nicolucci, R. Fornengo, A. Alessiato, A. Ozzello, L. Sciangula, N. Musacchio, G. Marelli, A. Corsi, V. Paciotti, R. Iannarelli, D. Antenucci, F. Chiaramonte, S. Leotta, V. Armentano, F. Mastinu, and D. Cucinotta

Subjects
medicine.medical_specialty, endocrine system diseases, Total cost, Endocrinology, Diabetes and Metabolism, Cost-Benefit Analysis, Medicine (miscellaneous), 030209 endocrinology & metabolism, Type 2 diabetes, Hypoglycemia, 03 medical and health sciences, Indirect costs, 0302 clinical medicine, Cost Savings, Absenteeism, medicine, Humans, Hypoglycemic Agents, 030212 general & internal medicine, Hospital Costs, Intensive care medicine, Retrospective Studies, Nutrition and Dietetics, Cost–benefit analysis, business.industry, nutritional and metabolic diseases, Type 2 Diabetes Mellitus, Retrospective cohort study, Health Care Costs, Length of Stay, medicine.disease, Hospitalization, Diabetes Mellitus, Type 1, Models, Economic, Diabetes Mellitus, Type 2, Italy, Emergency medicine, Sick leave, Health Resources, Health Expenditures, Sick Leave, Cardiology and Cardiovascular Medicine, business, Emergency Service, Hospital, Diabetes mellitus, Direct and indirect costs, Forecasting
Abstract

Background and aims To obtain an accurate picture of the total costs of hypoglycemia, including the indirect costs and comparing the differences between type 1 (T1DM) and type 2 diabetes mellitus (T2DM). Methods and results HYPOS-1 was a multicenter, retrospective cohort study which analyzed the data of 2229 consecutive patients seen at 18 diabetes clinics. Data on healthcare resource use and indirect costs by diabetes type were collected via a questionnaire. The domains of inpatient admission and hospital stay, work days lost, and third-party assistance were also explored. Resource utilization was reported as estimated incidence rates (IRs) of hypoglycemic episodes per 100 person-years and estimated costs as IRs per person-years. For every 100 patients with T1DM, 9 emergency room (ER) visits and 6 emergency medical service calls for hypoglycemia were required per year; for every 100 patients with T2DM, 3 ER visits and 1 inpatient admission were required, with over 3 nights spent in hospital. Hypoglycemia led to 58 work days per 100 person-years lost by the patient or a family member in T1DM versus 19 in T2DM. The costs in T1DM totaled €90.99 per person-year and €62.04 in T2DM. Direct and indirect costs making up the total differed by type of diabetes (60% indirect costs in T1DM versus 43% in T2DM). The total cost associated with hypoglycemia in Italy is estimated to be €107 million per year. Conclusions Indirect costs meaningfully contribute to the total costs associated with hypoglycemia. As compared with T1DM, T2DM requires fewer ER visits and incurs lower indirect costs but more frequent hospital use.

Published
2017

3. Clinical nephrology - miscellaneous

Author

C. Bantis, P. Heering, N.-M. Kouri, M. Siekierka-Harreis, M. Stangou, C. Schwandt, G. Efstratiadis, L.-C. Rump, K. Ivens, I. Haddiya, T. Houssaini Squalli, I. Laouad, B. Ramdani, R. Bayahia, G. G. Dimas, T. J. Tegos, S. G. Spiroglou, C. G. Pitsalidis, A. S. Sioulis, I. M. Karamouzis, C. G. Savopoulos, M. I. Karamouzis, A. G. Orologas, A. I. Hatzitolios, D. M. Grekas, D. Maixnerova, E. Jancova, I. Rychlik, R. Rysava, M. Merta, J. Reiterova, A. Kolsky, E. Honsova, J. Skibova, V. Tesar, Z. Kendi Celebi, R. Calayoglu, K. Keven, I. Kurultak, P. Mescigil, B. Erbay, O. Karatan, N. Duman, S. Erturk, G. Nergizoglu, S. Kutlay, S. Sengul, K. Ates, F. Marino, C. Martorano, M. Bellantoni, R. Tripepi, C. Zoccali, K. Ishizuka, Y. Harita, Y. Kajiho, H. Tsurumi, T. Asano, K. Nishiyama, N. Sugawara, H. Chikamoto, Y. Akioka, Y. Yamaguchi, T. Igarashi, M. Hattori, P. J. Heering, M. Sahay, D. V. Monova, S. V. Monov, Y.-y. Wang, H. Cheng, G.-q. Wang, H.-r. Dong, Y.-p. Chen, C.-j. Wang, Y.-l. Tang, E. Buti, E. Dervishi, F. Bergesio, G. Ghiandai, A. Mjeshtri, N. Paudice, A. L. Caldini, C. Nozzoli, E. E. Minetti, L. Sun, J. Feng, L. Yao, Q. Fan, J. Ma, L. Wang, T. Kirsanova, L. Merkusheva, N. Ruinihina, N. Kozlovskaya, G. Elenshleger, K. Turgutalp, U. Karabulut, T. Ozcan, I. Helvaci, A. Kiykim, A. Kaul, D. Bhadhuaria, R. sharma, N. Prasad, A. Gupta, C. Clajus, J. Schmidt, H. Haller, P. Kumpers, S. David, A. M. Sevillano, M. Molina, E. Gutierrez, E. Morales, E. Gonzalez, E. Hernandez, M. Praga, J. L. Conde Olasagasti, C. Vozmediano Poyatos, M. L. Illescas, S. Tallon, J. J. Uson Carrasco, A. Roca Munoz, F. Rivera Hernandez, G. Ismail, R. Jurubita, A. Andronesi, R. Bobeica, D. Zilisteanu, E. Rusu, C. Achim, A. Huerta, J. Caro, E. Gutierrez-Solis, A. Pasquariello, G. Pasquariello, M. Innocenti, G. Grassi, M. F. Egidi, O. Ozturk, A. Yildiz, C. B. Gul, K. Dilek, L. Tylicki, A. Jakubowska, E. Weber, S. Lizakowski, D. Swietlik, B. Rutkowski, A. Postorino, S. Costa, S. Cristadoro, G. Magazzu, G. Bellinghieri, V. Savica, M. Buemi, D. Santoro, Y. Lu, P. Shen, X. Li, Y. Xu, X. Pan, W. Wang, X. Chen, W. Zhang, H. Ren, N. Chen, B. P. Mitic, T. Cvetkovic, P. Vlahovic, R. Velickovic Radovanovic, V. Stefanovic, S. Kostic, V. Djordjevic, Q. Ao, Q. Ma, Q. Cheng, X. Wang, S. Liu, R. Zhang, S. Ozturk, S. Ozmen, D. Akin, R. Danis, M. Yilmaz, S. Hajri, S. Barbouche, H. Okpa, E. Oviasu, L. Ojogwu, N. Fotouhi, A. Ghaffari, F. Hamzavi, H. Nasri, M. Ardalan, A. Stott, A. Ullah, H. Anijeet, S. Ahmed, H. S. Kohli, R. Rajachandran, M. Rathi, V. Jha, V. Sakhuja, E. Yenigun, F. Dede, D. Turgut, E. Koc, H. Akoglu, S. Piskinpasa, R. Ozturk, A. Odabas, D. Bajcsi, G. Abraham, E. Kemeny, S. Sonkodi, P. Legrady, A. Letoha, K. Constantinou, Z. Ondrik, B. Ivanyi, G. Lucisano, N. Comi, P. Cianfrone, C. Summaria, V. Piraina, R. Talarico, C. Camastra, G. Fuiano, I. Proletov, E. Saganova, O. Galkina, E. Bogdanova, I. Zubina, V. Sipovskii, A. Smirnov, E. Bailly, D. Pierre, R. Kerdraon, O. Grezard, E. Gnappi, M. Delsante, M. Galetti, U. Maggiore, L. Manenti, M. J. Hasan, M. A. Muqueet, M. Mostafi, I. Chowdhury, W. Haque, T. Khan, Y.-J. Kang, E. J. Bae, H. S. Cho, S.-H. Chang, D. J. Park, G. Xu, H. Lin, Z. Hu, X. Yu, C. Xing, C. Mei, L. Zuo, Z. Ni, X. Ding, D. Li, Q. Zhang, X. Feng, and L. Lin

Subjects
Transplantation, medicine.medical_specialty, Nephrology, business.industry, medicine, Clinical nephrology, Intensive care medicine, business
Published
2013

4. Epidemiology and outcome research in CKD 5D

Author

L. Coentrao, C. Ribeiro, C. Santos-Araujo, R. Neto, M. Pestana, W. Kleophas, A. Karaboyas, Y. LI, J. Bommer, R. Pisoni, B. Robinson, F. Port, G. Celik, B. Burcak Annagur, M. Yilmaz, T. Demir, F. Kara, K. Trigka, P. Dousdampanis, N. Vaitsis, S. Aggelakou-Vaitsi, K. Turkmen, I. Guney, F. Turgut, L. Altintepe, H. Z. Tonbul, E. Abdel-Rahman, P. Sclauzero, G. Galli, G. Barbati, M. Carraro, G. O. Panzetta, M. Van Diepen, M. Schroijen, O. Dekkers, F. Dekker, A. Sikole, G. Severova- Andreevska, L. Trajceska, S. Gelev, V. Amitov, S. Pavleska- Kuzmanovska, H. Rayner, R. Vanholder, M. Hecking, B. Jung, M. Leung, F. Huynh, T. Chung, S. Marchuk, M. Kiaii, L. Er, R. Werb, C. Chan-Yan, M. Beaulieu, P. Malindretos, P. Makri, G. Zagkotsis, G. Koutroumbas, G. Loukas, E. Nikolaou, M. Pavlou, E. Gourgoulianni, M. Paparizou, M. Markou, E. Syrgani, C. Syrganis, J. Raimann, L. A. Usvyat, V. Bhalani, N. W. Levin, P. Kotanko, X. Huang, P. Stenvinkel, A. R. Qureshi, U. Riserus, T. Cederholm, P. Barany, O. Heimburger, B. Lindholm, J. J. Carrero, J. H. Chang, J. Y. Sung, J. Y. Jung, H. H. Lee, W. Chung, S. Kim, J. S. Han, K. Y. Na, A. Fragoso, A. Pinho, A. Malho, A. P. Silva, E. Morgado, P. Leao Neves, N. Joki, Y. Tanaka, M. Iwasaki, S. Kubo, T. Hayashi, Y. Takahashi, K. Hirahata, Y. Imamura, H. Hase, C. Castledine, J. Gilg, C. Rogers, Y. Ben-Shlomo, F. Caskey, J. S. Sandhu, G. S. Bajwa, S. Kansal, J. Sandhu, A. Jayanti, M. Nikam, L. Ebah, A. Summers, S. Mitra, J. Agar, A. Perkins, R. Simmonds, A. Tjipto, S. Amet, V. Launay-Vacher, M. Laville, A. Tricotel, C. Frances, B. Stengel, J.-Y. Gauvrit, N. Grenier, G. Reinhardt, O. Clement, N. Janus, L. Rouillon, G. Choukroun, G. Deray, A. Bernasconi, R. Waisman, A. P. Montoya, A. A. Liste, R. Hermes, G. Muguerza, R. Heguilen, E. L. Iliescu, V. Martina, M. A. Rizzo, P. Magenta, L. Lubatti, G. Rombola, M. Gallieni, C. Loirat, H. Mellerio, M. Labeguerie, B. Andriss, E. Savoye, M. Lassale, C. Jacquelinet, C. Alberti, Y. Aggarwal, J. Baharani, S. Tabrizian, S. Ossareh, M. Zebarjadi, P. Azevedo, F. Travassos, I. Frade, M. Almeida, J. Queiros, F. Silva, A. Cabrita, R. Rodrigues, C. Couchoud, J. Kitty, S. Benedicte, C. Fergus, C. Cecile, B. Sahar, V. Emmanuel, J. Christian, E. Rene, H. Barahimi, M. Mahdavi-Mazdeh, M. Nafar, M. Petruzzi, M. De Benedittis, M. Sciancalepore, L. Gargano, P. Natale, M. C. Vecchio, V. Saglimbene, F. Pellegrini, G. Gentile, P. Stroumza, L. Frantzen, M. Leal, M. Torok, A. Bednarek, J. Dulawa, E. Celia, R. Gelfman, J. Hegbrant, C. Wollheim, S. Palmer, D. W. Johnson, P. J. Ford, J. C. Craig, G. F. Strippoli, M. Ruospo, B. El Hayek, B. Hayek, E. Baamonde, E. Bosch, J. I. Ramirez, G. Perez, A. Ramirez, A. Toledo, M. M. Lago, C. Garcia-Canton, M. D. Checa, B. Canaud, B. Lantz, A. Granger-Vallee, P. Lertdumrongluk, N. Molinari, J. Ethier, M. Jadoul, B. Gillespie, C. Bond, S. Wang, T. Alfieri, P. Braunhofer, B. Newsome, M. Wang, B. Bieber, M. Guidinger, L. Zuo, X. Yu, X. Yang, J. Qian, N. Chen, J. Albert, Y. Yan, S. Ramirez, M. Beresan, A. Lapidus, M. Canteli, A. Tong, B. Manns, J. Craig, G. Strippoli, M. Mortazavi, B. Vahdatpour, S. Shahidi, A. Ghasempour, D. Taheri, S. Dolatkhah, A. Emami Naieni, M. Ghassami, M. Khan, K. Abdulnabi, P. Pai, M. Vecchio, M. A. Muqueet, M. J. Hasan, M. A. Kashem, P. K. Dutta, F. X. Liu, L. Noe, T. Quock, N. Neil, G. Inglese, M. Motamed Najjar, B. Bahmani, A. Shafiabadi, J. Helve, M. Haapio, P.-H. Groop, C. Gronhagen-Riska, P. Finne, R. Sund, M. Cai, S. Baweja, A. Clements, A. Kent, R. Reilly, N. Taylor, S. Holt, L. Mcmahon, M. Carter, F. M. Van der Sande, J. Kooman, R. Malhotra, G. Ouellet, E. L. Penne, S. Thijssen, M. Etter, A. Tashman, A. Guinsburg, A. Grassmann, C. Barth, C. Marelli, D. Marcelli, G. Von Gersdorff, I. Bayh, L. Scatizzi, M. Lam, M. Schaller, T. Toffelmire, Y. Wang, P. Sheppard, L. Neri, V. A. Andreucci, L. A. Rocca-Rey, S. V. Bertoli, D. Brancaccio, G. De Berardis, G. Lucisano, D. Johnson, A. Nicolucci, C. Bonifati, S. D. Navaneethan, V. Montinaro, M. Zsom, A. Bednarek-Skublewska, G. Graziano, J. N. Ferrari, A. Santoro, A. Zucchelli, G. Triolo, S. Maffei, S. De Cosmo, V. M. Manfreda, L. Juillard, A. Rousset, F. Butel, S. Girardot-Seguin, T. Hannedouche, M. Isnard, Y. Berland, P. Vanhille, J.-P. Ortiz, G. Janin, P. Nicoud, M. Touam, E. Bruce, B. Grace, P. Clayton, A. Cass, S. Mcdonald, Y. Furumatsu, T. Kitamura, N. Fujii, S. Ogata, H. Nakamoto, K. Iseki, Y. Tsubakihara, C.-C. Chien, J.-J. Wang, J.-C. Hwang, H.-Y. Wang, W.-C. Kan, N. Kuster, L. Patrier, A.-S. Bargnoux, M. Morena, A.-M. Dupuy, S. Badiou, J.-P. Cristol, J.-M. Desmet, V. Fernandes, F. Collart, N. Spinogatti, J.-M. Pochet, M. Dratwa, E. Goffin, J. Nortier, D. S. Zilisteanu, M. Voiculescu, E. Rusu, C. Achim, R. Bobeica, S. Balanica, T. Atasie, S. Florence, S. Anne-Marie, L. Michel, C. Cyrille, A. Strakosha, N. Pasko, S. Kodra, N. Thereska, A. Lowney, E. Lowney, R. Grant, M. Murphy, L. Casserly, T. O' Brien, W. D. Plant, J. Radic, D. Ljutic, V. Kovacic, M. Radic, K. Dodig-Curkovic, M. Sain, I. Jelicic, T. Hamano, C. Nakano, S. Yonemoto, A. Okuno, M. Katayama, Y. Isaka, M. Nordio, A. Limido, M. Postorino, M. Nichelatti, M. Khil, I. Dudar, V. Khil, I. Shifris, M. Momtaz, A. R. Soliman, M. I. El Lawindi, P. Dzekova-Vidimliski, S. Pavleska-Kuzmanovska, I. Nikolov, G. Selim, T. Shoji, R. Kakiya, N. Tatsumi-Shimomura, Y. Tsujimoto, T. Tabata, H. Shima, K. Mori, S. Fukumoto, H. Tahara, H. Koyama, M. Emoto, E. Ishimura, Y. Nishizawa, and M. Inaba

Subjects
Transplantation, medicine.medical_specialty, Nephrology, business.industry, Epidemiology, Medicine, business, Intensive care medicine, Outcome (game theory)
Published
2012

5. Clinical Activity and Safety of Anti-Programmed Death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in Patients (PTS) with Advanced Melanoma (MEL)

Author

Lada Mitchell, J. Pigozzo, K. Bennett, C.S.P. Lima, Silvia Park, Juan F. Medina, Antonio M. Grimaldi, David F. McDermott, Chi Hoon Maeng, R. Tanaka, L. Ridolfi, C.J.A. Punt, O.V. Korotkova, Amelia Lissia, D.M. Chen, W. Chang, J. De Vries, L. Pericleous, Ugo Marone, Corrado Caracò, Winald R. Gerritsen, E. Midena, C. Lebbé, Christian U. Blank, C. Brocia, E.F.D. Costa, R. Bassett, A. Sekulic, Tania Labiano, E. Fonsatti, D. Lawrence, Paola Queirolo, J.D. Wolchok, Stefano Mori, R. Dummer, C. Aliberti, Ruth Plummer, S. Francis, N. Vanhoutte, R. Wintherhalder, G.A.S. Nogueira, A. Amin, Jonathan D. Schwartz, M. Guida, C. Turtschi, Gerty Schreibelt, P. Mut, A. Ballesteros, S-H Lee, Anna C. Pavlick, Ester Simeone, M. Sini, K. Namikawa, R. Marconcini, Shibao Feng, Nicola Mozzillo, L. Veronese, C. Gamez, Merrick I. Ross, Donna Rowen, R. Labianca, T. Kirchhoff, M. Altomonte, Michele Maio, A. Batty, S. Yoo, James Larkin, Lev V. Demidov, Alessandro Testori, Omid Hamid, Sarvendra Kumar, Michael P. Brown, Jochen Utikal, J.A. Lopez Martin, R. Shapiro, Maria D. Lozano, N. Fischer, S. Ariad, B. Shafaeddin-Schreve, V. Chairion Sileni, M.K. Choi, Jung Yong Hong, Shreyaskumar Patel, Dimitris Bafaloukos, H. Yue, José I. Echeveste, M. Novy, M. Lebmeier, David R. Minor, F. Zambrana, M. Colombino, B. Campos, E. Muñoz, Simone M. Goldinger, D. Cumplido, P.L. Pilati, D. Lee, Giusy Gentilcore, G. Lucisano, J. Richards, Mario Sznol, F.S. Hodi, B. Merelli, Jeffrey S. Weber, M. Traversa, C. Oberkanins, Stephen M Murray, Suzanne L. Topalian, Vincent Brichard, I. Lazarev, D. Piazzalunga, F. De Galitiis, E. Wachter, C. Rubino, D. Opatt McDowell, Virginia Ferraresi, I.V. Samoylenko, M. Sereno, John A. Thompson, G. Colucci, P. Petrillo, M. Montañana, G. Di Monta, M. Maur, E. Bajetta, C. Oliveira, Kevin M. Chin, Sarah Danson, Anthony E. Oro, Igor Bondarenko, J.A. Rinck-Junior, W.J. Lesterhuis, E. Bertocci, A. Garcia Castano, T.N. Zabotina, S. Pisconti, S. Ellis, M. Hidalgo, A. Berrocal, Jeffrey A. Sosman, Sara Valpione, Miguel F. Sanmamed, Pier Francesco Ferrucci, Y. Sasajima, J. Perez, H. Linardou, F. De Rosa, J. Thompson, S. Stragliotto, Patrick Hwu, B.J. Coventry, M. Gillet, A.M. Di Giacomo, P.R. Hilfiker, L. Marchesi, Iman Osman, J. Rendleman, C. Nuzzo, G. Imberti, Edward McKenna, L. Di Guardo, Paul Nathan, I.N. Mikhaylova, Jenny Nobes, Antonio Cossu, Miguel Angel Idoate, Mario Mandalà, Giuseppe Palmieri, M. Ochoa de Olza, T. Nikoglou, M. Del Vecchio, B. Salaun, A. Cramarossa, J.M. Caminal, M. Biagioli, H. Tsuda, M.M. van Rossum, K. Harmankaya, J. Cortes, A.M. Moraes, H. Shaw, R. Danielli, S. Mosconi, John D. Hainsworth, Agop Y. Bedikian, G. Kriegshäuser, C.R. Scoggins, J. Valdivia, L. Pilla, R. Ridolfi, L.G. Campana, Christoph Rochlitz, M. Ma, V. Escrig, M.L. Cintra, I. Pesce, L. Calabrò, Karl D. Lewis, Russell S. Berman, Erik H.J.G. Aarntzen, Bart Neyns, T. Puertolas, J.A. Solomon, E. Castanon Alvarez, Georgia Kollia, F. Siannis, Katrin Conen, G.Z. Chkadua, Ana Arance, J.W. Lee, Caroline Robert, G.J. Lourenço, Jedd D. Wolchok, Lucia Benedetto, B.M. Smithers, N. Yamazaki, Axel Hauschild, A. Gupta, A. Gianatti, Luc Thomas, G. Rinaldi, A. Albano, D.P. Lawrence, F. Cognetti, A. Balogh, B. Rauscher, J.M. Wigginton, Carlo Tondini, W. Hwu, K. Baryshnikov, Y.S. Kim, A. Yakobson, J.M. Piulats, Ralf Gutzmer, Claus Garbe, R. Parrozzani, Kalijn F. Bol, M. Aglietta, V. Chiarion Sileni, Paolo A. Ascierto, M.R. Migden, P. Rojas, Nicholas E. Papadopoulos, V. De Giorgi, S. Martin Algarra, A. Tsutsumida, Ernie Marshall, S. Shang, S.V.L. Nicoletti, Joannes F M Jacobs, Anne Lynn S. Chang, J. Mayordomo, L. Cykowski, Sung Heon Kim, M. Gonzalez Cao, Sanjiv S. Agarwala, Michael S. Gordon, Carl G. Figdor, L. Alonso, Richard D. Carvajal, M.G. Bernengo, K. B. Kim, Daniela Massi, L. Dirix, O. Michielin, Nerea Gomez, Pippa Corrie, E. Ortega, Diana Giannarelli, E. Levchenko, H.R. Alexander, Alfonso Gurpide, P.M. LoRusso, Günther F.L. Hofbauer, J.D. Rinderknecht, B. Winn, L. Rivoltini, J. Hou, M. Aieta, S. Rossi, M.B. McHenry, Alejo Rodriguez-Vida, N. Eggmann, Alfred Zippelius, Y. Shao, G.J. Weiss, and Fabrizio Ayala

Subjects
Target lesion, medicine.medical_specialty, business.industry, Melanoma, Immediate family member, Hematology, medicine.disease, Clinical trial, Oncology, Internal medicine, Cohort, medicine, Previously treated, business, Survival rate, Progressive disease
Abstract

Purpose BMS-936558 is a monoclonal antibody that blocks the PD-1 co-inhibitory receptor expressed by activated T cells. This study describes its activity and safety in pts with previously treated advanced MEL. Methods BMS-936558 was administered IV q2wk to pts with various tumors at 0.1 - 10 mg/kg during dose-escalation and/or cohort expansion. Pts received up to 12 cycles (4 doses/cycle) of treatment or until unacceptable toxicity, confirmed progressive disease, or complete response. Clinical activity was assessed by RECIST v1.0. Results As of Feb 24, 2012, 104 MEL pts had received BMS-936558 at 0.1 (n = 17), 0.3 (n = 19), 1 (n = 31), 3 (n = 17), or 10 mg/kg (n = 20). ECOG performance status was 0/1/2 in 63/38/3 pts, respectively. Most pts (67/104) had received prior immunotherapy (IT); prior anti-CTLA-4, -PD-1, or -PD-L1 was not permitted. The number of prior therapies was 1 (39%), 2 (35%), or ≥3 (26%). Median therapy duration was 20 wks (range 2.0 - 121.7 wks). The incidence of grade 3 - 4 related AEs was 20% and included gastrointestinal (4%), endocrine (2%), and hepatobiliary disorders (1%). There were no drug-related deaths in MEL pts. Clinical activity (responses or prolonged stable disease) was observed at all doses (Table). Of the 26/94 (28%) evaluable responders, 19 (73%) are ongoing ranging from 1.9+ to 24.9+ months. For the 23 responders followed ≥6 months from first dose on study, 16 (70%) are progression free. ORs occurred in pts with visceral or bone metastases. Six pts (6%; 95% CI 2 - 13%) had prolonged SD (≥24 wk); 3 pts had a persistent decrease in target lesion tumor burden in the presence of new lesions and were not categorized as responders. Conclusions BMS-936558 had durable clinical benefit in pts with advanced MEL, including those who had received prior IT. Additional long-term follow-up data will be reported. Dose, (mg/kg) No. ptsa ORR, No. pts (%) [95% CI] PFSR at 24 wk (%) [95% CI] 0.1 14 4 (29) [8 - 58] 40 [13 - 66] 0.3 16 3 (19) [4 - 46] 31 [9 - 54] 1 27 8 (30) [14 - 50] 45 [26 - 65] 3 17 7 (41) [18 - 67] * 55 [30 - 80] 10 20 4 (20) [6 - 44] 30 [9 - 51] * 1 CR aResponse-evaluable pts dosed by 7/01/2011 ORR = objective response rate ([{CR + PR} ÷ n] × 100); PFSR = progression-free survival rate. Disclosure J. Sosman: Research Funding: Bristol-Myers Squibb (myself). M. Sznol: Consultant or Advisory Role: Bristol-Myers Squibb (myself, compensated). Research Funding: Bristol-Myers Squibb (myself, clinical trials funding). D.F. McDermott: Advisory Board Role: Bristol-Myers Squibb (myself). R. Carvajal: Research Funding: Bristol-Myers Squibb (myself). S.L. Topalian: Consultant or Advisory Role: Bristol-Myers Squibb (myself, immediate family member, uncompensated). Research Funding: Bristol-Myers Squibb (myself). J.M. Wigginton: Employment or Leadership Position: Bristol-Myers Squibb (myself, employment, compensated). Stock Ownership: Bristol-Myers Squibb (myself). G. Kollia: Employment or Leadership Role: Bristol-Myers Squibb (employment, myself, compensated). Stock Ownership: Bristol-Myers Squibb/BMY stocks (myself). A. Gupta: Employment or Leadership Role: Bristol-Myers Squibb (employment, myself, compensated). Stock Ownership: Bristol-Myers Squibb (myself). F.S. Hodi: Consultant or Advisory Role: Bristol-Myers Squibb (myself, uncompensated). Research Funding: Bristol-Myers Squibb (myself). All other authors have declared no conflicts of interest.

Published
2012

6. Progression & risk factors CKD 1-5 (1)

Author

D. Bolignano, L. Zanoli, S. Rastelli, C. Marcantoni, G. Coppolino, G. Lucisano, C. Tamburino, E. Battaglia, P. Castellino, P. Presta, L. Pedrelli, F. Iiadis, A. Ntemka, T. Didangelos, A. Makedou, M. Divani, E. Moralidis, K. Makedou, A. Gotzamani-Psarakou, D. Grekas, L. Selistre, V. Souza, O. Domanova, P. Cochat, B. Ranchin, A. Varennes, L. Dubourg, A. Hadj-Aissa, D. Leonardis, F. Mallamaci, G. Enia, M. Postorino, G. Tripepi, C. Zoccali, null MAURO Working Group, C. Donadio, A. Kanaki, F. Caprio, E. Donadio, D. Tognotti, L. Olivieri, S. Eloot, E. Schepers, D. Barreto, F. Barreto, S. Liabeuf, W. Van Biesen, F. Verbeke, G. Glorieux, G. Choukroun, Z. Massy, R. Vanholder, A. Chaaban, F. Torab, S. Abouchacra, B. Bernieh, Q. Hussein, M. Osman, N. Gebran, Y. Kayyal, H. Al Omary, N. Nagelkerke, M. Horio, E. Imai, Y. Yasuda, S. Takahara, T. Watanabe, S. Matsuo, A. Fujimi, S. Ueda, K. Fukami, N. Obara, S. Okuda, P. Pecchini, M. Mieth, R. Mass, F. Malberti, R. Quinn, P. Ravani, H. Fujii, K. Kono, K. Nakai, S. Goto, M. Fukagawa, S. Nishi, M. Havrda, J. Granatova, Z. Vernerova, J. Vranova, L. Hornova, J. Zabka, I. Rychlik, K. Kratka, L. De Nicola, P. Zamboli, S. Mascia, M. Calabria, M. Grimaldi, G. Conte, R. Minutolo, G. Gluhovschi, M. Modilca, A. Kaycsa, S. Velciov, C. Gluhovschi, F. Bob, L. Petrica, G. Bozdog, S. Methven, J. Traynor, C. Deighan, D. O'Reilly, M. MacGregor, M. Szotowska, J. Chudek, M. Adamczak, A. Wiecek, I. Dudar, I. Shifris, O. Loboda, N. Yanagisawa, M. Ando, K. Tsuchiya, K. Nitta, R. Heguilen, A. Liste, M. Canteli, G. Muguerza, L. Cohen, M. Ortemberg, R. Hermes, A. Bernasconi, D. Galli, N. Miani, E. Staffolani, R. Nicolais, M. S. Borzacchi, C. Tozzo, S. Manca di Villahermosa, N. Di Daniele, K. Musial, D. Zwolinska, G. Loriga, C. Carru, A. Zinellu, A. Milia, A. E. Satta, I. Frolova, A. Kuryata, L. Koppe, E. Kalabacher, C. Pelletier, A. Geloen, D. Fouque, C. Soulage, S. Feriozzi, J. Torras, M. Cybulla, K. Nicholls, G. Sunder-Plassmann, and M. West

Subjects
Transplantation, medicine.medical_specialty, Nephrology, business.industry, Internal medicine, medicine, business
Published
2011

7. Acute kidney injury - Human studies

Author

L. Locsey, I. Seres, F. Sztanek, M. Harangi, J. Padra, L. Asztalos, G. Paragh, C. A. Hutchison, A. Bevins, R. Langham, E. Mancini, O. Wirta, P. Cockwell, R. Keir, M. Vigano, A. Stella, N. Evans, M. Chappell, P. Fabbrini, M. Onuigbo, N. Onuigbo, S. Kim, J. H. Chang, J. Y. Jung, H. H. Lee, W. Chung, L. Zanoli, S. Rastelli, C. Marcantoni, C. Tamburino, P. Castellino, A. Cho, H. Choi, J. E. Lee, H. R. Jang, W. Huh, Y.-G. Kim, D. J. Kim, H. Y. Oh, N. Garcia-Fernandez, P. L. Martin-Moreno, N. Varo, J. M. Nunez-Cordoba, G. Schlieper, T. Kruger, M. Kelm, J. Floege, R. Westenfeld, A. J. Cho, S. Doganay, A. K. Oguz, I. Ergun, N. Bardachenko, O. Kuryata, L. Bardachenko, P. Ravani, F. Malberti, S. Pirelli, F. Scolari, B. Barrett, P. Presta, G. Lucisano, A. Rubino, F. Serraino, T. Amoruso, A. Renzulli, G. Fuiano, J. T. Kielstein, S. Tolk, A. Heiden, C. Kuhn, M. M. Hoeper, J. Lorenzen, M. Broll, V. Kaever, H. Burhenne, C. Hafer, H. Haller, O. Burkhardt, J. Kielstein, J. Zahalkova, N. Petejova, J. Strojil, K. Urbanek, S. Bertoli, C. Musetti, A. Cabiati, E. Assanelli, G. Lauri, I. Marana, M. De Metrio, M. Rubino, J. Campodonico, M. Grazi, M. Moltrasio, G. Marenzi, Z. Unarokov, T. Mukhoedova, P. Fidalgo, S. Coelho, B. Rodrigues, A. P. Fernandes, A. L. Papoila, F. Liano, K. Soto, J. Vanmassenhove, R. Vanholder, G. Glorieux, W. Van Biesen, R. Challiner, J. Ritchie, A. Hutchison, S. I. Zaharie, D. T. Maria, M. Zaharie, C. Vaduva, C. Grauntanu, D. Cana-Ruiu, E. Mota, M. Hayer, J. Baharani, M. Thomas, T. Eldehni, N. Selby, C. McIntyre, R. Fluck, N. Kolhe, R. M. Fagugli, F. Patera, P. R. Shah, K. K. Kaswan, V. B. Kute, A. V. Vanikar, M. R. Gumber, H. V. Patel, B. C. Munjappa, D. P. Enginner, V. V. Sainaresh, H. L. Trivedi, C. Teixeira, E. Nogueira, J. A. Lopes, E. Almeida, A. Pais de Lacerda, A. Gomes da Costa, C. Franca, F. Mariano, M. Morselli, D. Bergamo, Z. Hollo', S. Scella, M. Maio, C. Tetta, A. Dellavalle, M. Stella, G. Triolo, V. Cantaluppi, A. D. Quercia, P. Bertinetto, S. Giacalone, M. Tamagnone, E. Basso, E. Karvela, M. Gai, G. Leonardi, P. Anania, C. Guarena, C. M. Fenocchio, A. Pacitti, G. P. Segoloni, Y. O. Kim, H. G. Kim, B. S. Kim, H. C. S. Song, J.-K. Min, S. Y. Kim, W. D. Park, M. Dalboni, R. Narciso, M. Quinto, C. Grabulosa, E. Cruz, J. Monte, M. Durao, M. Cendoroglo, O. Santos, M. Batista, A. Bellasi, S. Giannone, A. Mordenti, A. Zanoni, A. Santoro, J. H. Lee, S. H. Ha, J. H. Kim, G. J. Lee, Y. C. Jung, P. Malindretos, G. Koutroumbas, A. Patrinou, G. Zagkotsis, P. Makri, I. Togousidis, C. Syrganis, G. Li Cavoli, C. Tortorici, L. Bono, A. Ferrantelli, C. Giammarresi, C. Zagarrigo, U. Rotolo, H. Kim, K. Jun, W. Choi, J.-M. Krzesinski, M.-C. Parotte, C. Vandevelde, J. Keenan, F. Dieterle, S. Sultana, M. Pinches, C. Ciorciaro, R. Schindler, V. Schmitz, J.-C. Gautier, X. Benain, J. Matchem, P. Murray, S. Adler, M. Haase, A. Haase-Fielitz, P. Devarajan, R. Bellomo, D. N. Cruz, G. Wagener, C. D. Krawczeski, J. L. Koyner, P. T. Murray, M. Zappitelli, S. Goldstein, K. Makris, C. Ronco, J. Martensson, C.-R. Martling, P. Venge, E. Siew, L. B. Ware, A. Ikizler, P. R. Mertens, A. Lacquaniti, A. Buemi, V. Donato, S. Lucisano, M. Buemi, S. Panagoutsos, P. Kriki, E. Mourvati, D. Tziakas, G. Chalikias, D. Stakos, S. Apostolakis, C. Tsigalou, T. Gioka, S. Konstantinides, V. Vargemezis, I. Torregrosa, C. Montoliu, A. Urios, C. Aguado, M. J. Puchades, M. A. Solis, I. Juan, R. Sanjuan, M. Blasco, J. Pineda, A. Carratala, C. Ramos, A. Miguel, A. Niculae, I. A. Checherita, R. Sandulovici, C. David, A. Ciocalteu, M. Espinoza, J. Hidalgo, E. Lorca, A. Santibanez, F. Arancibia, F. Gonzalez, M. Y. Park, E. J. Kim, S. J. Choi, J. K. Kim, S. D. Hwang, K.-h. Lee, S.-J. Seok, J.-O. Yang, E.-Y. Lee, S.-y. Hong, H.-w. Gil, E. Astapenko, A. Shutov, G. Savinova, V. Rechnik, M. J. Melo, M. Raimundo, A. Viegas, I. Camara, F. Antunes, M.-J. Kim, S. H. Kwon, S. W. Lee, J. H. Song, and J. W. Lee

Subjects
Transplantation, Pathology, medicine.medical_specialty, Human studies, Nephrology, business.industry, Acute kidney injury, medicine, medicine.disease, business
Published
2011

8. Predictors of Bubble Formation and Type Obtained with Pneumatic Dissection During Deep Anterior Lamellar Keratoplasty in Keratoconus

Author

Cristina Bovone, James Myerscough, Vincenzo Scorcia, Giovanna Carnovale Scalzo, Gabriele Piccoli, Giuseppe Giannaccare, Mauro Soda, Andrea Lucisano, Massimo Busin, Francesco Verdoliva, Marco Pellegrini, and Scorcia V, Giannaccare G, Lucisano A, Soda M, Scalzo GC, Myerscough J, Pellegrini M, Verdoliva F, Piccoli G, Bovone C, Busin M

Subjects
medicine.medical_specialty, Keratoconus, keratoconus, Bubble, Socio-culturale, Astigmatism, law.invention, 03 medical and health sciences, 0302 clinical medicine, law, Ectasia, Ophthalmology, medicine, pneumatic dissection, 030304 developmental biology, lamellar keratoplasty, pneumatic dissection, keratoconus, 0303 health sciences, Keratometer, DALK, keratoconus, bubble, predictors, business.industry, Retrospective cohort study, medicine.disease, Dissection, 030221 ophthalmology & optometry, Liquid bubble, lamellar keratoplasty, business
Abstract

PURPOSE: To identify predictors of bubble formation and type during big-bubble deep anterior lamellar keratoplasty (BB-DALK) performed in keratoconus at different stages of severity. DESIGN: Retrospective Cohort Study. METHODS: Setting: University Magna Græcia (Catanzaro, Italy); Study Population: Consecutive keratoconus patients undergoing BB-DALK from September 2014 to Feb- ruary 2019; Observation Procedure: Keratometric astigmatism, mean keratometry value (K-mean), highest keratometry value (K-max), thinnest point, anterior segment Optical Coherence Tomography (AS-OCT)-based stage of ectasia. Main Outcome Measures: Rate of bubble formation and type; number and fate of micro/macro-perforation; conver- sion to mushroom keratoplasty (MK); comparison of parameters in patients with bubble formation vs failure and in type 1 vs type 2 bubble; areas under the curves (AUC) of preoperative parameters for distinguishing between bubble types. RESULTS: Pneumatic dissection succeeded in 113/155 eyes (72.9%), with 100 type 1 bubbles (88.4%), 11 type 2 (9.8%) and 2 mixed-type (1.8%). Micro-perforations were managed conservatively in type-1 bubbles; macro-perforations occurring in both types of bubbles required conversion to MK. Preoperative K-mean and K-max values were significantly higher in eyes in which bubble formation succeeded (respectively, P=0.006 and P

Published
2020

9. Differential Activation of Signaling Pathways Involved in Cell Death, Survival and Inflammation by Radiocontrast Media in Human Renal Proximal Tubular Cells

Author

Michele Andreucci, Gaetano Lucisano, Mario Vitale, Giorgio Fuiano, Salvatore Salzano, Antonio Pisani, Teresa Faga, Bernardo Bertucci, Ashour Michael, Oscar Tamburrini, Massimo Sabbatini, M., Andreucci, G., Lucisano, T., Faga, B., Bertucci, O., Tamburrini, Pisani, Antonio, Sabbatini, Massimo, S., Salzano, M., Vitale, G., Fuiano, and A., Michael

Subjects
medicine.medical_specialty, Cell Survival, Pyridines, Protein Kinase, Pyridine, p38 mitogen-activated protein kinases, Protein Kinase Inhibitor, Contrast Media, Pharmacology, Biology, Toxicology, Cell Line, Proinflammatory cytokine, Kidney Tubules, Proximal, Internal medicine, medicine, Humans, Renal cell, Viability assay, Phosphorylation, Protein kinase A, Imidazole, Protein Kinase Inhibitors, Protein kinase B, Inflammation, Toxicity, Cell Death, Kinase, Imidazoles, Endocrinology, Signal transduction, Protein Kinases, Human, Signal Transduction
Abstract

Radiocontrast media (RCM) are widely used in clinical medicine but may lead to radiocontrast-induced nephropathy (RCIN). The pathogenesis of acute renal failure secondary to RCM is not fully understood, but direct toxic effects are believed to be a major cause of RCIN. We have investigated the effect of different types of RCM on signaling pathways known to play a role in cell death, survival, and inflammation. HK-2 cells were incubated with sodium diatrizoate and iomeprol (IOM) at a concentration of 75 mg I/ml for 2 h. Both RCM caused an increase in phosphorylation of p38 mitogen-activated protein kinase (MAPK) (p38) and c-Jun N-terminal kinases (JNKs) and NF-κB (at Ser 276), with sodium diatrizoate having a more drastic effect. Although cell viability was reduced significantly by both RCM, in cells pretreated with IOM the cell viability recovered over a 22-h time period after removal of the RCM. However, viability of diatrizoate-treated cells rose at 5 h but then fell at 22 h after removal of the RCM. The decrease in cell viability in diatrizoate-treated cells corresponded with an increase in phosphorylation of JNKs, p38, and NF-κB and a decrease in phosphorylation of Akt, signal transducer and activator of transcription 3, and forkhead box O3a, as well as poly (ADP-ribose) polymerase and caspase-3 cleavage. The recovery in viability of IOM-treated cells corresponded most notably with an increase in STAT3 phosphorylation and induction of Pim-1 kinase. There was also an increase in interleukin-8 release by diatrizoate-treated cells indicating the possibility of proinflammatory effects of RCM. A knowledge of the signaling pathways by which RCM exert their cytotoxic actions may help in finding future therapies for RCIN.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results